Wedbush Has Bullish Estimate for ZNTL FY2024 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities research analysts at Wedbush increased their FY2024 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research note issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($2.33) per share for the year, up from their prior forecast of ($2.83). Wedbush has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($3.02) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.66) EPS, Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.48) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($0.88) EPS.

ZNTL has been the topic of a number of other reports. Oppenheimer reissued an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $10.25.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $3.95 on Friday. The business’s 50-day moving average is $3.41 and its 200-day moving average is $5.52. Zentalis Pharmaceuticals has a 1 year low of $2.66 and a 1 year high of $18.07.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZNTL. ProShare Advisors LLC increased its holdings in Zentalis Pharmaceuticals by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock worth $243,000 after purchasing an additional 1,274 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after acquiring an additional 585,644 shares in the last quarter. Kennedy Capital Management LLC bought a new position in shares of Zentalis Pharmaceuticals in the first quarter valued at approximately $189,000. Opaleye Management Inc. bought a new position in shares of Zentalis Pharmaceuticals in the first quarter valued at approximately $3,152,000. Finally, SG Americas Securities LLC bought a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $58,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.